Get started

PFIZER

Opportunity on PFEA viewer on my Livestream Friday brought to my attention that Pfizer NYSE:PFE is coming off a major low (COVID Low) and has done a pullback to the 50% of the Impulse Move off said low. This is why I love doing Livestreams and having a trading community... idea crowdsourcing! I like these setups especially as the S&P 500 and many stocks within it are making new 52 Week highs leaving many wondering "what's a good reward/risk at this point?" The pullback on the Weekly bring price to the 50% of what I call an "Impulse Move" off the low: the first major reaction to confirm that price is respecting a low. See the Daily chart below for a lower timeframe view: I would not want to hold the position if price breached the major low. My first Target would be the 50% Retracement of the Bearish trend at 40.32. This sets up a proper 3 to 1 Reward/Risk Ratio. I will likely express this trade with shares purchased but may seek to buy Calls as well.
NYSE:PFELong
by norok
6
Long Short Idea: Short Coinbase, Long PfizerThe launch of a Bitcoin ETF could have a significant impact on Coinbase, the largest cryptocurrency exchange in the United States. Some analysts believe that the ETF could lead to a decline in trading volume on Coinbase, as investors may choose to trade Bitcoin through the ETF rather than directly on the exchange. Additionally, the ETF could put pressure on Coinbase's margins, as it would allow investors to borrow Bitcoin for less than they can borrow on the exchange. Pfizer, on the other hand, is a pharmaceutical company with a strong track record of innovation. The company has a pipeline of promising drugs that could generate significant revenue in the coming years. Pfizer is also well-positioned to benefit from the aging population in the United States and other developed countries. Short Coinbase There are several reasons why investors might want to short Coinbase. First, as mentioned above, the launch of a Bitcoin ETF could lead to a decline in trading volume on Coinbase. This would hurt Coinbase's revenue and profits. Second, the ETF could put pressure on Coinbase's margins. As investors borrow Bitcoin for less through the ETF, they will be less willing to pay high fees to borrow Bitcoin on Coinbase. This could squeeze Coinbase's profits. Long Pfizer There are also several reasons why investors might want to go long on Pfizer. First, the company has a strong track record of innovation. Pfizer has developed a number of blockbuster drugs, and the company has a pipeline of promising drugs that could generate significant revenue in the coming years. Second, Pfizer is well-positioned to benefit from the aging population in the United States and other developed countries. As the population ages, there will be a greater need for drugs to treat chronic diseases such as cancer and heart disease. Pfizer is a leader in these areas, and the company is well-positioned to capitalize on this trend. Conclusion The long-short idea of shorting Coinbase and going long on Pfizer is a contrarian trade. This trade is based on the belief that the launch of a Bitcoin ETF will be bad for Coinbase, but good for Pfizer. This trade is risky, but it has the potential to generate significant returns if the ETF does indeed hurt Coinbase's business. Disclaimer Please note that this is not investment advice. Investing in securities involves risk, and you could lose money. Before investing in any security, you should do your own research and consider your own risk tolerance.
NASDAQ:COINShort
by SabahEquityResearch
7
Health Canada Approval of ABRYSV Paves the Way for Pfizer In a significant stride towards enhancing public health, Health Canada has recently granted approval for Pfizer's groundbreaking bivalent Respiratory Syncytial Virus (RSV) vaccine, ABRYSVO™. This development is a crucial step in safeguarding both older adults and infants through maternal immunization. With the potential to revolutionize preventive healthcare, ABRYSVO™ addresses the prevention of lower respiratory tract diseases caused by RSV, catering to individuals aged 60 and above and infants from birth through 6 months. Protecting the Vulnerable Populations: The approval of ABRYSVO™ presents a new and vital option for protecting individuals most susceptible to severe RSV infections. Infants, particularly those under one year, face an increased risk of hospitalization due to RSV infection. Older adults also bear a significant burden of costs associated with the disease. Pfizer's vaccine aims to provide a comprehensive solution, mitigating the impact of RSV across different age groups and reducing the strain on healthcare resources. Maternal Immunization as a Strategic Approach: Dr. Darine El-Chaâr, a Maternal Fetal Medicine physician at The Ottawa Hospital, emphasizes the critical role of maternal immunization in bridging the vulnerability gap during the first few months of an infant's life. By administering vaccines to pregnant individuals, the approach not only protects the newborns but also safeguards mothers who may face an increased risk of severe disease compared to non-pregnant women. This strategic approach aligns with Pfizer's commitment to making a positive contribution to public health and community well-being. Pfizer's Commitment to Public Health: Andréa Mueller, Primary Care Portfolio Lead at Pfizer Canada, expresses pride in Pfizer's decades-long experience in vaccine development. The company's commitment to public health is evident in its dedication to providing effective solutions for preventing illness and reducing the strain on healthcare systems. The approval of ABRYSVO™ represents Pfizer's ongoing commitment to advancing healthcare solutions and making a positive impact on global well-being. Market Analysis: While the approval of ABRYSVO™ marks a significant milestone for Pfizer's contribution to public health, the technical analysis of Pfizer's stock indicates a falling trend channel in the medium to long term. Investors appear to have sold at lower prices over time, reflecting negative sentiments towards the company. However, it's essential to note that market trends are dynamic, and the approval of a groundbreaking vaccine may influence investor perceptions in the future. Conclusion: Pfizer's Health Canada approval for ABRYSVO™ brings hope for enhanced protection against RSV infections, benefiting both older adults and infants. The strategic focus on maternal immunization highlights Pfizer's commitment to addressing healthcare challenges comprehensively. As the company works towards making ABRYSVO™ available to Canadians, the market will likely closely watch how this groundbreaking vaccine contributes not only to public health but also to Pfizer's future trajectory in the pharmaceutical landscape.
NYSE:PFE
by DEXWireNews
Pfizer.... Start buildingPfizer is one of those companies that we all feel has been shady and the stock value shows it. As much as human emotion can draw this value down, hedge funds and smart money will start stepping in now. The chart says it all. We are talking about one of the longest running publically traded companies folks, this will rebound. Its not a matter of if, but when. I have started a minor position in Pfizer today and plan to DCA weekly small amount until we form a bullish trend. Good luck!
NYSE:PFELong
by farmtrader15
1
Pfizer (NYSE: $PFE) Stock SinksKey Takeaway 1. Shares of Pfizer tanked Wednesday as investors digested the subpar guidance, falling as much as 9% to below $26 in morning trading, hitting their lowest intraday share price since 2013. That’s the largest single-day drop for Pfizer since January 2009. 2. Pfizer said Wednesday it expects 2024 revenue to come in between $58.5 billion and $61.5 billion, representing roughly zero growth from 2023’s forecasts and coming in well below analysts’ average 2024 projected sales of $62.6 billion, according to FactSet. 3. Notably, Pfizer said it expects 2024 sales for its Covid products—Paxlovid pills and the Comirnaty vaccine—to be about $8 billion, a nearly 90% drop from the roughly $57 billion of revenue its Covid series brought in last year.
NYSE:PFEShort
by DEXWireNews
Pfizer Drops After Pulling Obesity-Drug Study Following PatientPfizer will retool its obesity drug efforts, but the delay is a blow to the group's ambitions to challenge Novo Nordisk and Lilly in the fast-developing space. Pfizer (NYSE: PFE) - shares slumped Friday after the drugmaker said it would not advance a study of its two-dose obesity treatment, following a high level of side effects in patients involved in the Phase II trial. Pfizer said it would instead focus on a single-dose option. Trials of its danuglipron treated showed good results in weight loss but induced vomiting and nausea in patients, which led to what it called "high discontinuation rates" compared with those taking a placebo. Pfizer's Mikael Dolsten, president of worldwide research and development, in late October called the danuglipron study "our main opportunity here for getting data to review for obesity, in fact, to diabetes" in a call with investors. For Pfizer, a Setback in Weight-loss Market The decision marks a significant setback in Pfizer's ambitions to enter the weight-loss drug market, which is currently dominated by Novo Nordisk's Wegovy. Pfizer rival Eli Lilly (LLY) - Get Free Report last month also won approval for its own weight-loss treatment, Zepbound, from the Food and Drug Administration. At last check Pfizer stock was trading off 4.7% just above $28.91 That's a bit more than half its 52-week high near $55, set in mid-December 2022. Pfizer in October slashed its full-year sales and profit forecasts amid a slump in demand for covid treatments, It told investors it would write off around $4.6 billion in inventories of Paxlovid, its oral covid treatment, while taking a further $5.5 billion noncash charge against its third-quarter earnings. Price Momentum PFE is trading near the bottom of its 52-week range and below its 200-day simple moving average. What does this mean? Investors have been pushing the share price lower, and the stock still appears to have downward momentum. This is a negative sign for the stock's future value.
NYSE:PFEShort
by DEXWireNews
Pfizer long-term movement after a deep correction - risky paperH i, I looked at Pfizer's chart and it looks like this deep correction won't stop until the $30 zone. The fact that side effects have developed worldwide due to the Covid vaccine and many people have filed lawsuits against pharmaceutical companies probably also plays a role in this deep decline. There is a lot of money in the pharmaceutical industry, so I think that the companies will have plenty of money to cover possible legal costs. And since in several countries they have signed papers that they request the vaccination on their own responsibility, the exclusion of liability will be justified in many cases. The $30 zone seems like a perfect turning point because I see it as a strong level. If the $30 zone holds, we will most likely look at the $40 zone, which also coincides with an important Fibonacci level. Do not forget. This does not constitute investment advice. Do your own research before entering a position. Regards In extreme cases, the $27 level is also possible.
NYSE:PFE
by XOX_XOX
1
Pfizer's (PFE) Ulcerative Colitis Pill Etrasimod Gets FDA NodPfizer PFE announced that the FDA has granted approval to its oral, once-daily pill called etrasimod to treat moderately-to-severely active ulcerative colitis (UC). The oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator will be marketed by the brand name of Velsipity (2 mg dose). The approval for etrasimod was based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12. These studies evaluated the safety and efficacy of a daily 2mg dose of oral etrasimod in UC patients who had failed treatment with a JAK inhibitor. Both studies achieved their primary endpoint of clinical remission over placebo and all key secondary endpoints. An application seeking the approval of etrasimod is also under review in the EU, with a decision from the European Medicines Agency anticipated in first-half 2024. Velsipity (etrasimod) was added to Pfizer’s inflammation and immunology portfolio with the March 2022 acquisition of Arena Pharmaceuticals. The oral, once-daily pill for UC, a chronic condition, is an advanced therapy, which, if approved, will offer patients an opportunity to achieve steroid-free remission. Pfizer’s stock has declined 37.4% so far this year against an increase of 8.5% for the industry.
NYSE:PFELong
by DEXWireNews
Pfizer's Stock: Is it Worth the Investment ?Pfizer's Stock: Is it Worth the Investment Amidst Challenges and Opportunities? Pfizer, a pharmaceutical powerhouse, has made headlines in recent years, primarily for its groundbreaking coronavirus vaccine. Despite achieving over $100 billion in annual revenue last year, the company's stock has witnessed a significant decline of approximately 35% in the current year. This prompts the question: Why has Pfizer's share price dipped despite robust financial performance, and is it still a worthwhile investment? In this article, we'll delve into the factors affecting Pfizer's stock and assess whether it presents an attractive investment opportunity. Challenges on the Horizon The decline in Pfizer's stock can be attributed to investor concerns regarding the sustainability of vaccine sales in a post-pandemic world. As vaccine demand wanes, the company faces declining revenues from products like Comirnaty and Paxlovid, with projections of double-digit revenue declines compared to the previous year. Moreover, Pfizer is grappling with the imminent patent expirations of key drugs like Eliquis and Ibrance, which could result in revenue losses totaling $17 billion from 2025 through 2030. Assessing the Risks Pfizer's transition from government contracts to commercial sales introduces some risk, as commercial purchasers typically do not commit to extensive supply agreements years in advance. Additionally, the looming patent cliff poses a revenue challenge that Pfizer must address. Positive Developments Despite these challenges, Pfizer has several positive developments to consider. Comirnaty and Paxlovid may still provide steady recurring revenue, albeit at lower levels. Pfizer envisions the coronavirus market evolving into something akin to the flu shot market, potentially generating substantial billion-dollar revenue, given its market leadership. Earnings from coronavirus-related products have empowered Pfizer to pursue acquisitions and initiatives to fuel long-term growth. Last year, Pfizer acquired four companies expected to contribute over $10 billion to revenue by 2030. Furthermore, a planned acquisition of oncology specialist Seagen could add an additional $10 billion in revenue. Addressing the patent cliff, Pfizer is actively working to mitigate revenue losses. It anticipates generating $20 billion in revenue by 2030 from ongoing product launches. The company is midway through its most substantial wave of product releases, aiming for 19 launches in an 18-month period, with contributions expected in the latter half of this year. Pfizer projects that business deals, ongoing product launches, and potential pipeline launches could result in non-coronavirus revenue of up to $84 billion in 2030. Is Pfizer a Worthy Investment? Considering these factors, Pfizer appears well-prepared to offset potential revenue losses and foster growth in the years ahead. The revenue outlook for 2030 is promising, even without factoring in coronavirus product sales. Additionally, Pfizer's shares are currently trading at an attractive valuation of around 10 times forward earnings estimates. In conclusion, Pfizer seems to be a prudent investment choice at this juncture. While immediate stock price gains may not be expected, investors entering at the current price point may enjoy dividends in the near term, as Pfizer is committed to rewarding shareholders. Furthermore, the potential for improved share price performance in the future makes Pfizer a compelling investment opportunity amidst its transitional phase. Previous ( Winning ) Idea:
NYSE:PFEShort
by FOREXN1
6
PFIZER Buy signal but only on the short-term.Pfizer (PFE) has been trading within a Channel Down pattern since the start of the year and on Friday it registered the strongest green 1D candle since the recent Lower Low leg started in August. This is technically the start of the new rebound leg towards a new Lower High. Those have been priced within the 1D MA50 (blue trend-line) and 1D MA100 (green trend-line), never breaking above the latter. We are therefore targeting the 1D MA50 again at 34.50, an average estimate based on the previous three Lower High legs. Note that this is only a short-term trade as the long-term trend remains heavily bearish within the Channel Down. Only a 1D candle closing above the 1D MA100 can justify a longer term buy targeting the 1D MA200 (orange trend-line). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:PFELong
by TradingShot
7
Pfizer (PFE) -> It Is Now Or NeverMy name is Philip, I am a German swing-trader with 4+ years of trading experience and I only trade stocks , crypto , options and indices 🖥️ I only focus on the higher timeframes because this allows me to massively capitalize on the major market swings and cycles without getting caught up in the short term noise. This is how you build real long term wealth! In today's anaylsis I want to take a look at the bigger picture on Pfizer. At the moment Pfizer stock is once again retesting major sructure at the psychological $33 level which already acted as pretty strong support in the past. Considering that the next support level below current price is at $27, Pfizer is now trading at a pretty decisive potential turning point and has not yet broken structure towards the downside. - - - - - - - - - - - - - - - - - - - - I know that this is a quite simple trading approach but over the past 4 years I've realized that simplicity and consistency are much more important than any trading strategy. Keep the long term vision🫡
NYSE:PFELong
by basictradingtv
20
PFE, Huge Triangle-Formation With Possible Breakout Ahead!Hello Traders Investors And Community, welcome to this analysis where we are looking at the 4-hour timeframe perspective of stock value PFIZER, the recent events, the current formation structure, what needs to be fulfilled that the stock confirms properly and what are possible trading opportunities when the stock has confirmed. As the main stock-market has recovered from the huge corona-breakdowns seen this year there where stock which gained strength out of the crisis and stocks which just stayed in a bearish state, although the health sector surged in demand because of the health crisis and people wanting to live more sustainable lives PFIZER is still somewhat in a sideways movement where it has to confirm and therefore show the ability that it has the strength to move beyond this sideways correction, therefore, I detected some important and interesting signals which can determine the follow-up destiny. When looking at my chart you can watch this huge possible ascending-triangle-formation where the stock already confirmed several times the upper and lower boundary, furthermore, it noted several times above the 100- and 400-EMA which you can watch marked in blue and orange in the chart, this is a good sign because on the other side there are stocks which trading below these EMA structures. As the stock is approaching the upper boundary another time now we can expect it to confirm as resistance and therefore move on to test the lower boundary of the triangle-formation another time, when the stock manages to stabilize in this boundary where also a coherent support-cluster lies as you can watch it in my chart the potential is given that the stock goes on to confirm the huge ascending--triangle-formation with a final break above it which will cause the bullish rising and an appointment to higher targets. For now, it is highly important that the stock holds the substantially lower boundary sustainable and does not fall below it where the possibility is not big currently but it should by no means kept by side easily. Compared to other stocks which already moved above and confirmed new highs this stock has definitely some room to go, the breakout when it happens can be traded the best way with a conservative entry after the upper boundary has confirmed, it is also possible to open up an immediate position but this would be the riskier variety, traders should decide according to individual risk preference, and to secure the proper confirmation it is from high importance that corona increases not heavily again and the real economic situation stabilizes further from the heavy breakdowns because when it does not this can cause bearish rumors in all global markets and therefore possible downside ahead which can invalidate the scenario. In this manner, thank you for watching, support for more market insight, have a great day, and all the best to you! There are many roads to prosperity, but one must be taken. Information provided is only educational and should not be used to take action in the markets.
NYSE:PFE
by VincePrince
9
PFE - Pfizer drop from medain line.Here's not much on the chart. But what you see is evident. The pitchforks median line is respected by price many times. And this time it's the same. But there's a reason why this time price could flush down to the L-MLH. Indexes are weaker and weaker. The first profit target for me is either the L-MLH, or the A/R (yellow) line. The Action/Reaction line is projected from above's swing range. So, there we have another one to the short side. I have more short charts than longs. However, I always try to keep my overall portfolio balanced. How? There are always industries and sectors which perform to the long side, even when markets tank. It's simple but it takes effort.
NYSE:PFEShort
by Tr8dingN3rd
Covid 2023 - Profiting from CorruptionHello everyone Josh here again. I’m sure by now you’ve already heard mumblings of Covid’s imminent return. We are seeing everything from colleges to hospitals start to implement Covid policies. The news cycle is starting to warn of a dangerous flu season/Covid return. Governments around the world are now updating their Covid policies and sleepy Joe’s White House is still pushing for the mass vaccination and experimentation on of human guinea pigs around the world. With all this being said, it is my idea that we are about to go back into lockdown/full Covid policy mode. Although I wish this was not the case, I do intend to profit from it. Illustrated is the Moderna chart, I use this, as it was one of the first assets I made money off of during the last pandemic, in fact, you can still go back and see my old idea on my page about Moderna when I called it at around sub $60. However, this could’ve been any chart from Amazon and Netflix to hospital sectors, to e-commerce platforms like Shopify. Basically, anything that will go up during a full-scale, pandemic/lockdown. If my gut feeling is right, and we are going to go into a full-scale lock down, it might be one of the easiest plays of the century. During the last pandemic, we saw airlines, cruise lines, casinos and resorts and a myriad of other sectors collapse to unprecedented lows. I expect something similar to happen this time around, to varying degrees of severity. Many people made millions by shorting assets last pandemic, I think we are setting ourselves up for the perfect storm to profit. Look for stocks to long and short. Ignore the noise and make your money off of the lies of the global elite. Below is an AI rendered breakdown of this idea. Thank you so much for reading. Please follow and like my ideas :) Investment Thesis: Navigating Pandemic-Related Market Trends I. Introduction: The investment thesis centers around capitalizing on potential market shifts resulting from pandemic-related policies enacted by governments and corporations globally. II. Market Outlook: Anticipating the implementation of pandemic-related rules and regulations, which could include mask mandates, lockdowns, and travel restrictions. III. Asset Allocation Strategy: A. Long Positions: E-commerce Dominance: As witnessed during the previous pandemic, e-commerce platforms like Amazon thrived. This trend is likely to persist as people turn to online shopping for convenience and safety. Entertainment Streaming: Companies like Netflix benefited from increased demand for home entertainment. Expect this trend to continue, making streaming platforms potentially profitable investments. Pharmaceutical Giants: Pfizer and Moderna played pivotal roles in vaccine development during the Covid pandemic. Their expertise positions them well for potential future vaccine requirements or pharmaceutical innovations. Healthcare Stocks: Hospital and healthcare-related stocks may experience increased demand as health services remain crucial during pandemic periods. B. Short Positions: Travel and Hospitality Sectors: Historical data shows that airlines, cruise liners, resorts, and casinos experienced significant declines during the last pandemic due to travel restrictions and reduced consumer spending. IV. Risk Considerations: While historical patterns suggest certain sectors will benefit and others may decline during pandemics, unforeseen variables can impact market dynamics. Careful monitoring and adaptability are essential. V. Diversification and Hedging: To mitigate risks, consider diversifying your portfolio across industries and asset types. This approach helps balance potential losses from short positions with gains from long positions. VI. Exit Strategy: Regularly reassess the investment landscape, keeping an eye on shifts in policies, vaccination rates, and economic indicators. Be prepared to adjust your positions accordingly to optimize gains or minimize losses. VII. Conclusion: In light of potential pandemic-related policies, a strategic investment approach involves capitalizing on e-commerce, streaming, pharmaceutical, and healthcare sectors, while shorting travel and hospitality sectors. Prudent risk management, diversification, and a proactive exit strategy will be pivotal in navigating the ever-evolving market landscape. Please note that investment decisions involve inherent risks, and it's advisable to consult with a qualified financial advisor before executing any investment strategy.
NASDAQ:MRNA
by Helios_Capital_Investment
Unveiling the Potential of Pfizer Pharmaceutical Stock in 2023Are you searching for a lucrative investment opportunity that promises great returns in 2023? Look no further as we unveil the hidden potential of Pfizer Pharmaceutical stock. In this blog post, we will delve into the compelling reasons why investing in Pfizer is not only a smart move but also an incredibly exciting. From groundbreaking innovations to robust financial performance, join us as we explore why Pfizer is poised to be a game-changer in the pharmaceutical industry and how you can reap substantial rewards by including it in your investment portfolio. Don’t miss out on this exclusive insight into what could be your most profitable venture yet! Monthly price action is supporting a strong bullish correction in the following months. Pfizer is one of the world’s leading pharmaceutical companies and was at the forefront of developing a vaccine for Covid-19 in 2020. The stock price reflected the impact of the vaccine until December 2021, when the stock plunged, losing almost 50% of its value. It’s then when a longer-term demand imbalance takes control and helps us make a high-probability decision to buy and hold shares of Pfizer PFE stock.
NYSE:PFE
by AlfonsoMoreno
Pfizer getting ready to make rapid movesPfizer is one of the world’s leading pharmaceutical company specializes in vaccines, hospitals, internal medicines and inflammation and immunology. Their manufacturing capacity is 4 billion tablets annually and supplied in neighboring countries of India. Pfizer CMP is 3866. Negative aspects of the company are high valuation (P.E. = 28.3), MFs are decreasing stake. Positive aspects of the company are increasing annual net profits, improving cash from operations annual, no debt, FIIs are increasing stake and zero promoter pledge. Entry can be taken after closing above 3901. Targets in the stock will be 3975 and 4006. Long term target in the stock will be 4069 and 4129. Stop loss in the stock should be maintained at closing below 3696.
NSE:PFIZERLong
by Happy_Candles_Investment
Pfizer to stall at major resistance?Pfizer - Medium Term - We look to Sell at 39.88 (stop at 41.08) Bespoke resistance is located at 40. 40.14 has been pivotal. 40.37 has been pivotal. Daily signals are bearish. We look for a temporary move higher. Our profit targets will be 37.08 and 36.58 Resistance: 37.05 / 38.30 / 39.00 Support: 36.03 / 35.50 / 35.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group.
NYSE:PFEShort
by VantageMarkets